Skip to content

Sequential determination of the half effective dose of remazolam for hysteroscopic surgery

Sequential determination of the half effective dose of remazolam for hysteroscopic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082414
Enrollment
Unknown
Registered
2024-03-28
Start date
2024-03-28
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases of the female reproductive system, unspecified

Interventions

Rimazolam mesylate group:Rimazolam mesylate exposure

Sponsors

Putuo People's Hospital Affiliated to Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients undergoing elective hysteroscopic surgery were aged 18 to 60 years with ASA class I-II.

Exclusion criteria

Exclusion criteria: Anatomical malformations of the uterus or cervical canal, surgical procedures for uterine adhesions with complex operations, expected injuries, and long surgical times (>2H), comorbid cardiovascular and respiratory diseases, severe cardiac, pulmonary, hepatic, and renal insufficiencies, a history of prolonged smoking and alcohol abuse, allergies to propofol, benzodiazepines, and other anesthetic medications, a history of alcohol or drug abuse, patients with severe preoperative anemia or those needing intraoperative blood transfusions, psychiatric disorders, and patients with moderately to severely severe sleep apnea.

Design outcomes

Primary

MeasureTime frame
MOAA/S score;

Secondary

MeasureTime frame
VAS score;Mean arterial pressure;Heart rate;Sp02;

Countries

China

Contacts

Public ContactZhifeng Chen

Putuo People's Hospital Affiliated to Tongji University

dzfc2013@163.com+86 180 1979 0339

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026